Zynex (NASDAQ:ZYXI)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Thursday, TipRanks reports. They presently have a $22.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 75.72% from the company’s current price.
A number of other research analysts have also commented on the stock. Northland Securities reiterated a “buy” rating and issued a $22.50 price target on shares of Zynex in a research note on Friday, July 16th. Zacks Investment Research upgraded shares of Zynex from a “sell” rating to a “hold” rating in a research note on Thursday, September 30th. Finally, B. Riley upgraded shares of Zynex from a “neutral” rating to a “buy” rating and increased their target price for the stock from $19.00 to $19.50 in a research report on Friday, July 16th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.60.
ZYXI traded up $0.97 during trading on Thursday, hitting $12.52. The company had a trading volume of 6,640 shares, compared to its average volume of 399,129. The firm’s 50-day moving average price is $12.78 and its 200 day moving average price is $14.46. The company has a quick ratio of 5.83, a current ratio of 6.95 and a debt-to-equity ratio of 0.01. Zynex has a one year low of $10.66 and a one year high of $22.89. The company has a market capitalization of $435.20 million, a PE ratio of 83.40 and a beta of 0.85.
In other news, CEO Thomas Sandgaard sold 177,320 shares of the stock in a transaction on Friday, August 6th. The shares were sold at an average price of $15.17, for a total transaction of $2,689,944.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 44.28% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Captrust Financial Advisors lifted its stake in shares of Zynex by 5,705.7% in the first quarter. Captrust Financial Advisors now owns 2,032 shares of the company’s stock valued at $31,000 after buying an additional 1,997 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Zynex by 24.8% during the first quarter. Bank of Montreal Can now owns 5,938 shares of the company’s stock valued at $90,000 after purchasing an additional 1,179 shares in the last quarter. State of Tennessee Treasury Department lifted its position in shares of Zynex by 18.1% during the first quarter. State of Tennessee Treasury Department now owns 6,946 shares of the company’s stock valued at $106,000 after purchasing an additional 1,065 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Zynex by 87.1% during the second quarter. BNP Paribas Arbitrage SA now owns 7,195 shares of the company’s stock valued at $112,000 after purchasing an additional 3,349 shares in the last quarter. Finally, SRS Capital Advisors Inc. bought a new position in shares of Zynex during the second quarter valued at about $120,000. Institutional investors and hedge funds own 31.02% of the company’s stock.
Zynex, Inc engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.
Featured Story: Liquidity
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.